Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Archives of neurology - 1 Sept 2003

Maddalena Alessia, Papassotiropoulos Andreas, Müller-Tillmanns Britta, Jung Hans H, Hegi Thomas, Nitsch Roger M, Hock Christoph

Abstract excerpt

BACKGROUND: The antemortem diagnosis of Alzheimer disease (AD) requires time-consuming and costly procedures. Therefore, biochemical tests that can direct the physician rapidly to the correct diagnosis are highly desirable. Measurement of single biochemical markers in cerebrospinal fluid (CSF), s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Antibodies, Monoclonal
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Glycogen Synthase Kinase 3

Share to Neuropsychological Tests

Share to Peptide Fragments

Share to ROC Curve

Source

Identifiers

PMID: 12975284
DOI: 10.1001/archneur.60.9.1202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12975284-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.PMID 12975284Read ↗

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal DementiasSemantic proximity Read ↗

CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.Semantic proximity Read ↗

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Semantic proximity Read ↗

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.Semantic proximity Read ↗

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's diseaseSemantic proximity Read ↗

The Use of Proteomics in Biomarker Discovery in Neurodegenerative DiseasesSemantic proximity Read ↗

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.Semantic proximity Read ↗

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.Semantic proximity Read ↗

Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia.Semantic proximity Read ↗

Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADSemantic proximity Read ↗

Phosphorylated Tau-Aβ42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal FluidSemantic proximity Read ↗

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.